Group 1 - WinVest Acquisition Corp. has postponed its Special Meeting of stockholders originally scheduled for August 22, 2025, with a new date to be announced later [1] - The record date for the Special Meeting is set for September 30, 2025, and there are no changes to the location, purpose, or proposals to be acted upon [1] - Stockholders will vote on proposals related to the proposed initial business combination involving WinVest Acquisition Corp., WinVest (BVI) Ltd., Xtribe P.L.C., and Xtribe (BVI) Ltd. [2] Group 2 - The deadline for holders of the Company's common stock to submit shares for redemption in connection with the Business Combination has been extended to two business days before the new date of the Special Meeting [3] - Stockholders can withdraw previously submitted redemption requests at any time prior to the Special Meeting by contacting the Company's transfer agent [3] Group 3 - A sufficient number of stockholders have already voted to approve the proposed Business Combination, but not all conditions for closing have been satisfied, prompting the postponement [4] - WinVest Acquisition Corp. is a blank check company formed to effect a merger, share exchange, asset acquisition, stock purchase, reorganization, or similar business combination [5] Group 4 - The Company, WinVest BVI, and Xtribe BVI have filed a Registration Statement with the SEC, which includes a Proxy Statement/Prospectus that has been mailed to stockholders [6] - Investors can obtain free copies of the Registration Statement and other relevant documents through the SEC's website [7]

LITTLE ROCK, Ark., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Dillard’s, Inc. (DDS-NYSE) (the “Company” or “Dillard’s”) announced that the Board of Directors declared a cash dividend of $0.30 per share on the Class A and Class B Common Stock of the Company. The dividend is payable November 3, 2025 to shareholders of record as of September 30, 2025. CONTACT:Julie J. Guymon, C.P.A. 501-376-5965julie.guymon@dillards.com ...

Core Viewpoint - Bubblr Inc. (d/b/a Ethical Web AI) addresses recent promotional activities related to its common stock, asserting that these activities did not materially affect trading [2][5]. Promotional Activities - On August 18, 2025, the Company received an inquiry from OTC Markets regarding promotional activities, marking the first awareness of such activities [2]. - The promotional activities involved a sponsored article by Stellar Partners LLC and Penzance Partners LLC, which the Company had no prior knowledge of [3]. - The Company denies any involvement in the creation, distribution, or payment for the promotional materials, asserting that none of its management or directors had editorial control over them [4]. Financial Transactions - The promotional materials disclosed that Stellar Partners LLC was paid $100,000 for investor relations and marketing services, which the Company categorically denies [5]. - The Company has not engaged any third-party service providers for investor relations or marketing services in the last 12 months [6][8]. - The only known sale of the Company's securities was by CEO Stephen Morris, who sold 1,307 shares in a private transaction to existing shareholders [7]. Company Operations - The Company has not issued shares or convertible instruments at discounted prices relative to the current market rate [8].

Core Insights - Teads Holding Co. is scheduled to participate in two investor conferences in September 2025, including the Citi's 2025 Global TMT Conference and Jefferies TechTrek 2025 Conference [1][2] Group 1: Investor Conferences - Teads will have a fireside chat at the Citi's 2025 Global TMT Conference on September 3, 2025, from 2:10 to 2:45 PM EST [2] - The company will also participate in one-on-one meetings with investors at the Jefferies TechTrek 2025 Conference on September 10-11, 2025, in Tel Aviv, Israel [2] Group 2: Company Overview - Teads Holding Co. was formed from the merger of Outbrain Inc. and TEADS on February 3, 2025, and officially changed its corporate name on June 6, 2025 [3] - Teads operates as an omnichannel outcomes platform for the Open Internet, focusing on delivering full-funnel results for marketers through predictive AI technology [3] - The company collaborates with over 10,000 publishers and 20,000 advertisers globally, employing nearly 1,800 people across more than 30 countries [3]

Core Points - UTime Limited has received a notification from Nasdaq indicating non-compliance with the minimum stockholders' equity requirement of $2,500,000 as per Nasdaq Listing Rule 5550(b)(1) [1] - The company's reported stockholders' equity in its Form 20-F for the year ended March 31, 2025, is below the required threshold [1] - UTime does not meet the alternatives of market value of listed securities or net income from continuing operations as of August 14, 2025 [1] Compliance Plan - The notification does not have an immediate effect on the listing of UTime's class A ordinary shares on Nasdaq [2] - UTime has 45 calendar days, until September 29, 2025, to submit a plan to regain compliance with the minimum stockholders' equity standard [2] - If the compliance plan is accepted by Nasdaq, it may grant an extension of up to 180 calendar days from the date of the notification letter [2] Disclosure - The press release serves to disclose the receipt of the notification from Nasdaq in accordance with Nasdaq Listing Rule 5815(a) [3]

Core Viewpoint - AVITA Medical, Inc. is actively engaging with investors through participation in three upcoming investor conferences in September 2025, highlighting its commitment to investor relations and market presence [1][2]. Company Overview - AVITA Medical is a leading therapeutic acute wound care company focused on delivering transformative solutions aimed at optimizing wound healing and accelerating patient recovery [4]. - The company's flagship product, the RECELL System, is FDA-approved for treating thermal burn and trauma wounds, utilizing the patient's own skin to create Spray-On Skin™ Cells for improved clinical outcomes [4]. - In addition to RECELL, AVITA holds exclusive rights in the U.S. for manufacturing and distributing PermeaDerm and Cohealyx™, both of which are innovative wound care products [4]. International Market Presence - The RECELL System is approved for a variety of applications in international markets, including Australia, Europe, and Japan, demonstrating its global reach and regulatory compliance [5]. Upcoming Events - AVITA Medical will host investor meetings at the Cantor Global Healthcare Conference on September 4, 2025, the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, and the Lake Street Capital Markets 9th Annual Best Ideas Growth Conference on September 11, 2025 [8]. - A live audio webcast of the Morgan Stanley fireside chat featuring CEO Jim Corbett will be available for replay for 90 days on the company's Investor Relations website [3].

Core Insights - LifeVantage Corporation will release its financial results for the fourth quarter and full fiscal year ended June 30, 2025, on September 4, 2025, after market close [1] - A conference call for investors will take place on the same day at 2:30 p.m. Mountain Time [1] Financial Results Announcement - The financial results will cover the fourth quarter and the full fiscal year ending June 30, 2025 [1] - The announcement will be made after the stock market closes on September 4, 2025 [1] Conference Call Details - Investors can participate in the live call by dialing (877) 704-4453 from the U.S. or (201) 389-0920 for international callers [2] - A telephone replay will be available approximately two hours after the call and will last until September 18, 2025 [2] Webcast Information - A live webcast of the conference call will be available on the Investor Relations section of the company's website [3] - The webcast will be archived for approximately 30 days [3] Company Overview - LifeVantage Corporation is a pioneer in nutrigenomics, focusing on how nutrition and natural compounds can enhance health at the cellular level [4] - The company offers a range of products, including the Protandim® family, TrueScience® Liquid Collagen, and various health-supporting nutrients [4] - LifeVantage was founded in 2003 and is headquartered in Lehi, Utah [4]

Company Overview - Methode Electronics, Inc. is a leading global supplier of custom-engineered solutions for user interface, lighting system, and power distribution applications [5] - The company operates in various end markets including transportation, cloud computing infrastructure, construction equipment, and consumer appliances [6] - Methode's business is segmented into Automotive, Industrial, and Interface [6] Upcoming Financial Results - The company will release its first quarter fiscal 2026 results for the period ended August 2, 2025, on September 3, 2025, after market close [1] - A conference call and webcast will be held on September 4, 2025, at 10:00 a.m. CDT to review financial and operational highlights [2] - The call will be led by President and CEO Jon DeGaynor and CFO Laura Kowalchik [2] Participation Details - To participate in the conference call, dial 888-506-0062 (domestic) or 973-528-0011 (international) at least five minutes prior to the start [3] - A simultaneous webcast can be accessed through the company's website on the Investors page [3] - A replay of the teleconference will be available until September 18, 2025, by dialing 877-481-4010 with passcode 52837 [4]

Core Insights - Red Violet, Inc. will present at the Midwest IDEAS Investor Conference on August 26-27, 2025, in Chicago [1] - Camilo Ramirez, Senior Vice President of Finance and Investor Relations, will lead the presentation and host investor meetings on August 27, 2025 [1] Company Overview - Red Violet specializes in analytics and information solutions, focusing on identity intelligence through proprietary technologies [2] - The company's solutions facilitate real-time identification and location of individuals, businesses, and assets, serving purposes such as identity verification, risk mitigation, and fraud detection [2] - The intelligent platform, CORE™, is designed for enterprises but adaptable for organizations of all sizes, transforming large datasets into actionable intelligence [2]

Core Insights - Oculis Holding AG reported strong progress in its clinical pipeline, focusing on unmet medical needs in ophthalmology and neuro-ophthalmology, with significant advancements in its key product candidates [2][4][16] Clinical Development - OCS-01 is in pivotal Phase 3 DIAMOND trials, fully enrolled with over 800 patients across 119 global sites, aiming to be the first eye drop treatment for diabetic macular edema (DME), with topline results expected in Q2 2026 [4][5] - Privosegtor (OCS-05) has shown promising Phase 2 ACUITY trial results in acute optic neuritis, indicating significant improvements in visual function and neuroprotective benefits, with plans for a Phase 2/3 trial expected to initiate in 1H 2026 [4][5] - Licaminlimab (OCS-02) is preparing for a genotype-based Phase 2/3 trial in dry eye disease, expected to start in 2H 2025, following positive results from previous studies [4][5] Financial Overview - As of June 30, 2025, Oculis reported cash, cash equivalents, and short-term investments totaling $201.3 million, providing a cash runway into early 2028 [4][6] - Research and development expenses for Q2 2025 were $18.1 million, a decrease from $18.2 million in Q2 2024, primarily due to the timing of completed trials [6][13] - The year-to-date net loss for the first half of 2025 was $67.9 million, compared to $41.5 million for the same period in 2024, driven by advancements in clinical programs and adjustments in warrant liabilities [6][14] Market Potential - DME affects approximately 37 million people globally, representing a market opportunity of around $5 billion, highlighting the significant unmet medical needs for early intervention [5] - The neuroprotective potential of Privosegtor opens opportunities for various neuro-ophthalmology and neurology indications, addressing high unmet needs in these areas [5][16]